NewAmsterdam Pharma Company N.V Financials
NewAmsterdam Pharma Company N.V (NAMS) reported $22.5M in revenue for fiscal year 2025, down 50.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
A development-stage biotech is funded mainly through financing inflows while research spending and operating cash use remain far above reported revenue.
The business’s commercial scale is not yet absorbing its cost base: FY2025 revenue fell to$22.5M from$45.6M in FY2024, while R&D stayed at$141.8M . Financing cash flow fell to$29.5M in FY2025, after$659.5M in FY2024, making the balance sheet’s expansion primarily financing-led rather than internally funded.
Cash consumption is largely operating and development spending, not heavy physical reinvestment: FY2025 free cash flow was
The balance sheet is equity-funded: FY2025 total liabilities were
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of NewAmsterdam Pharma Company N.V's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
NewAmsterdam Pharma Company N.V scores 21.43, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.3B) relative to total liabilities ($85.9M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
NewAmsterdam Pharma Company N.V passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
NewAmsterdam Pharma Company N.V reported a net loss of $203.0M while operations used $147.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
NewAmsterdam Pharma Company N.V generated $22.5M in revenue in fiscal year 2025. This represents a decrease of 50.6% from the prior year.
NewAmsterdam Pharma Company N.V's EBITDA was -$225.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 28.0% from the prior year.
NewAmsterdam Pharma Company N.V reported -$203.0M in net income in fiscal year 2025. This represents an increase of 16.1% from the prior year.
NewAmsterdam Pharma Company N.V earned -$1.72 per diluted share (EPS) in fiscal year 2025. This represents an increase of 32.8% from the prior year.
Cash & Balance Sheet
NewAmsterdam Pharma Company N.V recorded an outflow of $148.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 7.0% from the prior year.
NewAmsterdam Pharma Company N.V held $490.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
NewAmsterdam Pharma Company N.V's ROE was -29.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 2.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
NewAmsterdam Pharma Company N.V invested $141.8M in research and development in fiscal year 2025. This represents a decrease of 6.3% from the prior year.
NewAmsterdam Pharma Company N.V invested $246K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 63.4% from the prior year.
Not reported for fiscal year 2025.
NAMS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| Revenue | $7.1M | $22.5M-50.6% | $45.6M+223.4% | $14.1M-86.3% | $102.7M | N/A |
| R&D Expenses | $149.2M | $141.8M-6.3% | $151.4M-5.0% | $159.4M+83.8% | $86.7M+199.4% | $29.0M |
| SG&A Expenses | $102.3M | $106.4M+51.0% | $70.4M+87.2% | $37.6M+92.9% | $19.5M+225.0% | $6.0M |
| Operating Income | -$244.4M | -$225.7M-28.0% | -$176.3M+3.6% | -$183.0M-5043.9% | -$3.6M+89.8% | -$35.0M |
| Interest Expense | N/A | N/A | N/A | N/A | $287K-30.2% | $411K |
| Income Tax | N/A | N/A | -$1K-103.7% | $27K | N/A | N/A |
| Net Income | -$258.7M | -$203.0M+16.1% | -$242.0M-36.7% | -$177.0M-682.0% | -$22.6M+45.8% | -$41.8M |
| EPS (Diluted) | — | -$1.72+32.8% | -$2.56-19.1% | -$2.15 | -$1.19 | -$3.81 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NAMS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Total Assets | $769.3M-11.0% | $864.6M+149.1% | $347.1M-27.5% | $478.5M | N/A |
| Current Assets | $675.7M-21.7% | $863.4M+149.0% | $346.8M-27.4% | $478.0M | N/A |
| Cash & Equivalents | $490.0M-36.5% | $771.7M+126.7% | $340.4M-27.2% | $467.7M | N/A |
| Total Liabilities | $85.9M-19.9% | $107.1M+82.5% | $58.7M+21.2% | $48.4M | N/A |
| Current Liabilities | $85.8M-19.8% | $106.9M+114.3% | $49.9M+38.4% | $36.1M | N/A |
| Total Equity | $683.4M-9.8% | $757.5M+162.7% | $288.4M-32.9% | $430.1M+477.9% | -$113.8M |
| Retained Earnings | -$762.4M-36.5% | -$558.6M-76.2% | -$317.0M-126.4% | -$140.0M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
NAMS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$143.5M | -$147.8M+6.8% | -$158.6M-12.3% | -$141.2M-1424.1% | $10.7M+136.1% | -$29.5M |
| Capital Expenditures | $260K | $246K-63.4% | $672K+2700.0% | $24K-89.1% | $221K+820.8% | $24K |
| Free Cash Flow | -$143.7M | -$148.0M+7.0% | -$159.2M-12.7% | -$141.2M-1452.4% | $10.4M+135.4% | -$29.5M |
| Investing Cash Flow | -$34.9M | -$174.9M-178.3% | -$62.8M-261766.7% | -$24K+89.1% | -$221K-820.8% | -$24K |
| Financing Cash Flow | $41.7M | $29.5M-95.5% | $659.5M+7300.2% | $8.9M-97.7% | $391.9M+362.7% | $84.7M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NAMS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Operating Margin | -1002.9% | -386.9% | -1298.6% | -3.5% | N/A |
| Net Margin | -902.1% | -531.1% | -1256.2% | -22.0% | N/A |
| Return on Equity | -29.7%+2.3pp | -31.9%+29.4pp | -61.4%-56.1pp | -5.3% | N/A |
| Return on Assets | -26.4%+1.6pp | -28.0%+23.0pp | -51.0%-46.3pp | -4.7% | N/A |
| Current Ratio | 7.88-0.2x | 8.08+1.1x | 6.95-6.3x | 13.26 | N/A |
| Debt-to-Equity | 0.130.0x | 0.14-0.1x | 0.20+0.1x | 0.11 | N/A |
| FCF Margin | -657.8% | -349.5% | -1002.4% | 10.2% | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where NewAmsterdam Pharma Company N.V Ranks
Frequently Asked Questions
What is NewAmsterdam Pharma Company N.V's annual revenue?
NewAmsterdam Pharma Company N.V (NAMS) reported $22.5M in total revenue for fiscal year 2025. This represents a -50.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is NewAmsterdam Pharma Company N.V's revenue growing?
NewAmsterdam Pharma Company N.V (NAMS) revenue declined by 50.6% year-over-year, from $45.6M to $22.5M in fiscal year 2025.
Is NewAmsterdam Pharma Company N.V profitable?
No, NewAmsterdam Pharma Company N.V (NAMS) reported a net income of -$203.0M in fiscal year 2025.
What is NewAmsterdam Pharma Company N.V's EBITDA?
NewAmsterdam Pharma Company N.V (NAMS) had EBITDA of -$225.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is NewAmsterdam Pharma Company N.V's return on equity (ROE)?
NewAmsterdam Pharma Company N.V (NAMS) has a return on equity of -29.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is NewAmsterdam Pharma Company N.V's free cash flow?
NewAmsterdam Pharma Company N.V (NAMS) recorded an outflow of $148.0M in free cash flow during fiscal year 2025. This represents a 7.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is NewAmsterdam Pharma Company N.V's operating cash flow?
NewAmsterdam Pharma Company N.V (NAMS) recorded an outflow of $147.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are NewAmsterdam Pharma Company N.V's total assets?
NewAmsterdam Pharma Company N.V (NAMS) had $769.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are NewAmsterdam Pharma Company N.V's capital expenditures?
NewAmsterdam Pharma Company N.V (NAMS) invested $246K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does NewAmsterdam Pharma Company N.V spend on research and development?
NewAmsterdam Pharma Company N.V (NAMS) invested $141.8M in research and development during fiscal year 2025.
What is NewAmsterdam Pharma Company N.V's current ratio?
NewAmsterdam Pharma Company N.V (NAMS) had a current ratio of 7.88 as of fiscal year 2025, which is generally considered healthy.
What is NewAmsterdam Pharma Company N.V's debt-to-equity ratio?
NewAmsterdam Pharma Company N.V (NAMS) had a debt-to-equity ratio of 0.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is NewAmsterdam Pharma Company N.V's return on assets (ROA)?
NewAmsterdam Pharma Company N.V (NAMS) had a return on assets of -26.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does NewAmsterdam Pharma Company N.V's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, NewAmsterdam Pharma Company N.V (NAMS) held $728.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $147.8M over that year. Dividing the one by the other, the reported balance equals about 59 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is NewAmsterdam Pharma Company N.V's Altman Z-Score?
NewAmsterdam Pharma Company N.V (NAMS) has an Altman Z-Score of 21.43, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is NewAmsterdam Pharma Company N.V's Piotroski F-Score?
NewAmsterdam Pharma Company N.V (NAMS) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are NewAmsterdam Pharma Company N.V's earnings high quality?
NewAmsterdam Pharma Company N.V (NAMS) reported a net loss of $203.0M while operations used $147.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is NewAmsterdam Pharma Company N.V?
NewAmsterdam Pharma Company N.V (NAMS) scores 66 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.